Who are FVIII products's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Recombinant Von Willebrand factor, ReFacto, von Willebrand factor, Plasma-derived FVIII/VWF concentrate, Intravenous infusions of Xyntha, Recombinant Human Coagulation FVIII.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fviii-products.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

FVIII products — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

FVIII products (FVIII products) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Coagulation factor VIII replacement therapy. Area: Hematology.

phase 2 Coagulation factor VIII replacement therapy Factor VIII Hematology Small molecule Live · refreshed every 30 min

Target snapshot

FVIII products (FVIII products) — Bayer. FVIII products replace or supplement the missing or defective clotting factor VIII in the blood to help the blood to clot normally.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
FVIII products TARGET	FVIII products	Bayer	phase 2	Coagulation factor VIII replacement therapy	Factor VIII
Recombinant Von Willebrand factor	Recombinant Von Willebrand factor	Nicoletta C Machin	marketed	Recombinant coagulation factor	Von Willebrand factor receptor (GPIb-IX-V complex on platelets); Factor VIII binding site
ReFacto	ReFacto	Wyeth is now a wholly owned subsidiary of Pfizer	marketed	Recombinant clotting factor	Factor VIII (antihemophilic factor)
von Willebrand factor	von Willebrand factor	National Center for Research Resources (NCRR)	marketed	Coagulation factor replacement	Von Willebrand factor receptor (GPIb-IX-V complex on platelets); Factor VIII binding site
Plasma-derived FVIII/VWF concentrate	Plasma-derived FVIII/VWF concentrate	Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico	marketed	Coagulation factor concentrate	Factor VIII and von Willebrand Factor
Intravenous infusions of Xyntha	Intravenous infusions of Xyntha	Pfizer	marketed	Recombinant coagulation factor VIII	Coagulation factor VIII
Recombinant Human Coagulation FVIII	Recombinant Human Coagulation FVIII	Sinocelltech Ltd.	marketed	Coagulation factor replacement therapy	Coagulation Factor VIII

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Coagulation factor VIII replacement therapy class)

Bayer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). FVIII products — Competitive Intelligence Brief. https://druglandscape.com/ci/fviii-products. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing